Annovis Bio, Inc. (ANVS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Annovis Bio, Inc. on January 28, 2026. The company is incorporated in Delaware and its common stock trades on the New York Stock Exchange under the symbol ANVS. The filing serves as a Regulation FD disclosure regarding a corporate webinar scheduled for the same date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing to announce a presentation and does not contain audited or unaudited financial statements.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing solely discloses the scheduling of an informational webinar.
Guidance, Outlook, and Management Commentary
Management has announced a webinar to be conducted on January 28, 2026. The presentation materials for this event are included as Exhibit 99 and incorporated by reference. No specific financial guidance, risk factors, or unusual items are detailed within the body of this 8-K filing.
Investor Verification Checklist
- Review Exhibit 99 (Webinar Presentation) for detailed operational updates and potential financial guidance.
- Verify the company's cash runway and burn rate in the most recent 10-Q or 10-K, as this 8-K contains no liquidity data.
- Confirm the status of clinical trials or product development milestones discussed in the webinar materials.
- Check for any subsequent filings that may provide the financial data referenced in the webinar.